Literature DB >> 16436756

In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.

M M Traczewski1, S D Brown.   

Abstract

The in vitro activities of doripenem, imipenem, levofloxacin, piperacillin, ceftazidime, aztreonam, tobramycin, and cefepime were determined for 160 isolates of Pseudomonas aeruginosa (82 from cystic fibrosis [CF] patients) and 34 isolates of Burkholderia cepacia. Doripenem MIC90s were lower than those of all other comparative agents against all isolates combined and against all P. aeruginosa isolates. Doripenem was as active as levofloxacin and 2- to 32-fold more active than the other comparative agents against B. cepacia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436756      PMCID: PMC1366868          DOI: 10.1128/AAC.50.2.819-821.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

Review 1.  Burkholderia cepacia. Management issues and new insights.

Authors:  J J LiPuma
Journal:  Clin Chest Med       Date:  1998-09       Impact factor: 2.878

2.  Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.

Authors:  M J Richards; J R Edwards; D H Culver; R P Gaynes
Journal:  Crit Care Med       Date:  1999-05       Impact factor: 7.598

3.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

  3 in total
  14 in total

1.  In vitro activity of doripenem against Burkholderia cepacia complex isolates from non-cystic fibrosis patients.

Authors:  Lipika Singhal; Vikas Gautam; Mandeep Kaur; Pallab Ray
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

Review 2.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients.

Authors:  Zoya Hojabri; Mohammad Ahangarzadeh Rezaee; Mohammad Reza Nahaei; Mohammad Hossein Soroush; Morteza Ghojazadeh; Tahereh Pirzadeh; Mostafa Davodi; Mona Ghazi; Reza Bigverdi; Omid Pajand; Mohammad Aghazadeh
Journal:  Adv Pharm Bull       Date:  2013-02-07

4.  Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Authors:  Karen E Bowker; Alan R Noel; Sharon G Tomaselli; Heather Elliott; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2012-06-19       Impact factor: 5.191

5.  In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.

Authors:  Aryun Kim; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

Review 6.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

7.  Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.

Authors:  Xuan Qin; Danielle M Zerr; Michael A McNutt; Jessica E Berry; Jane L Burns; Raj P Kapur
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

8.  Safety of high-dose doripenem in adult patients with cystic fibrosis.

Authors:  Seth Strawbridge; Michael D Nailor
Journal:  Ther Adv Drug Saf       Date:  2016-04-08

Review 9.  New antimicrobial strategies in cystic fibrosis.

Authors:  Mireille van Westreenen; Harm A W M Tiddens
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

10.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.